🇺🇸 FDA
Pipeline program

Radiotherapy combined with TKI and Anti-PD-1 Antibody

RTI

Unknown other active

Quick answer

Radiotherapy combined with TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma is a Unknown program (other) at Jian Li with 1 ClinicalTrials.gov record(s).

Program details

Company
Jian Li
Indication
Stage IIIA Hepatocellular Carcinoma
Phase
Unknown
Modality
other
Status
active

Clinical trials